摘要:

Seventy patients with local squamous cell carcinoma of the esophagus were treated between 1981 and 1990 with preoperative chemotherapy, surgical resection, and possible postoperative radiation therapy and/or chemotherapy. Chemotherapy included two cycles of 5-fluorouracil (1000 mg/m2) by continuous intravenous infusion on days 1–4 and cisplatin (100 mg/m2) on day 4. Complete clinical response (CCR) was achieved in 28 (41%) patients, partial clinical response (PCR) in 17 (25%), and no response in 23 (34%).Fifty-five (81%) patients were resected, 6 (9%) were explored, and 7 (10%) were unable to have surgery.Microscopic analysis of 55 resected patients showed 50 (91%) with active tumor, 1 (2%) with necrotic tumor, and 4 (7%) with a pathological complete response to chemotherapy.Twenty-six of the 55 resected patients (47%) had no gross evidence of disease at the time of surgical inspection. Median overall survival was 21.86 months (range 2–107 months) for all patients and 26.71 months (range 2–107 months) for resected patients. Actuarial S-year survival rate was 31% for all patients and 39% for resected patients. Prolonged survival correlates with complete clinical response to chemotherapy, low pathological stage of disease, and successful resection of the lesion.

ISSN:0735-7907    

DOI:10.3109/07357909309024826

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

Between March 1986 and December 1987, two groups of consecutive patients with advanced breast cancer underwent epidoxorubicin (Epidx) monochemotherapv. Twenty-three patients (group A) received Epidx at a dose of 60 mg/m2and 27 (group B) at a dose of 120 mg/m2(i.v. every 3 weeks). No patient had undergone anthracycline treatment before entering the study. Age ranged from 39 to 70 years (mean 52) in group A and from 35 to 69 (mean 50 in group B). The main sites of involvement were liver (5 patients in group A and 10 in group B), lung (4 and 5 patients. respectively), bone (7 and 8 patients, respectively), and soft tissue (6 and 5 patients, respectively).The number of courses of therapy ranged from 4 to 10 (mean 7.4) in group A and from 3 to 10 (mean6.6)in group B. Tumor response and toxic effects were graded according to World Health Organization criteria. CR + PR were 35% in group A and 67% in group B (chi square = 3.862, p<0.05). Results were analyzed at 130 weeks from the beginning of the therapy. At this time, survival was 9% in group A and 15% in group B, with a median survival time of 61 weeks (range 18–130) and 77 weeks (range 24–130), respectively. No patient in group A showed cardiac toxicity higher than grade 2 during or after the treatment, whereas in group B, 2 patients developed congestive heart failure after a cumulative Epidx dose of 1080 and 1200 mg/m2. Treatment delays, to allow recovery of white blood cells, were infrequent and occurred only in patients previously subjected to chemotherapy. No patient required hospitalization for sepsis, and alopecia was reversible in all patients.Our data demonstrate that there is a relationship between Epidx dose and response rate in advanced breast cancer.

ISSN:0735-7907    

DOI:10.3109/07357909309024827

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

Rectal mucosal (epithelial) proliferation labeling indices (LI) have been widely used as a risk marker for colorectal cancer and as an intermediate end-point in chetno-prevention studies. The purpose of this study was to determine whether the presence of cancer preoperatively altered the LI and whether these LI could be used over the long term us a market for colon cancer. We studied 25 patients (18 with colorectal cancer and 7 with benign colonic diseases) who were admitted for colonic resection. Biopsies for thymidine LI were taken before, during, and 4 and 7 months after the operation. The preoperative LI of cancer patients was higher, but not significantly, than that of noncancer patients (5.22 5 3.54 and 4.11±1.34%, respectively,p= 0.28). The intraoperative LI was significantly higher than the preoperative LI (8.08±4.00 and 4.90±3.07%, respectively;p= 0.004). After 4 and 7 months, the LI was not significantly different from the preoperative LI (p= 0.60 and 0.89, respectively). Resection of a colonic segment did not affect the level of proliferation over time. Therefore, it is unlikely that LI can be used as a marker to predict local recurrence after curative resection of colorectal cancer.

ISSN:0735-7907    

DOI:10.3109/07357909309024828

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

In this study of 25 central nervous system (CNS) tumor-bearing rats, the CNS biodistribution of intravenously administered, indium-labeled liposomes was investigated. In 16 animals, the blood-brain barrier and blood-tumor barrier were modified using intracarotid administration of etoposide. In control animals, analysis by autoradiography and well-counting experiments demonstrated uptake of liposomes in the tumor-bearing hemisphere (% injected dose/g tissue = 0.135) with minimal uptake in the non-tumor-bearing hemisphere (% injected doselg tissue = 0.007),p<0.01. Unilaterul intracurotid etoposide administration enhanced li-posome uptake in both hemispheres—0.215 and 0.023 (tumor-bearing and non-tumor-bearing), respectively. The presence of meningeal tumor involvement in non-tumor-implanted hemispheres increased liposomul uptake IO-fold. These findings may have clinical applicability in designing therapeutic protocols for the treatment of CNS tumors.

ISSN:0735-7907    

DOI:10.3109/07357909309024829

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

We performed radioimmunoscintigraphy (RIS) and / or pharmacokinetic (PCK) studies in 12 patients with primury or metastatic colorectal carcinoma, utilizing an intravenous administration of 1–4 mCi (1 mg) of1311-B72.3 monoclotial antibody. Metastatic lesions were correctly identified in 418 patients by RIS. Two patients with small lesions (>2 cm diameter) had a false-negative RIS scan. Two patients had a true-negative RIS scan. Optimal images were obtained at I week peek postinjection. PCK studies showed that the plasma clearance of131I-B72.3 was biexponetial with an alpha-phase half-life ranging from 0.5 to 7.1 hr and a beta-phase half-life ranging from 47.5 to 85.3 hr. Systemic and renal clearance data indicated that131I-B72.3 was cleared very slowly and almost entirely by deiodination.This pilot study wus conducted to gain an understanding of the pharmacokinetics of this radiolabeled antibody. On the basis of these data, we are now studying second-generation antibodies as part of our long-range objectives to incorporate them in early detection and treatment protocols.

ISSN:0735-7907    

DOI:10.3109/07357909309024830

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

Thirty patients with previously untreated and measurable or evaluable advanced sofr tissue sarcoma entered this phase II study. Median age was 53 years (range: 24–71 years). Starting dose of Epirubicin was 100 mg/m2IV bolus on day I combined with Ifosfamide, 2.5 g/m2, as a 6-hr IV infusion on day I and day 2 with uroprotection with Uromitexan, 1.6 g/m2, on day 1 and day 2. This schedule was repeated every 3 weeks. In case of minimal myelosuppression, the dose of Epirubicin was increased by 10 mg/m2up to 130 mg/m2. Ifosfamide dosage was not increased. Mean cumulative dose of Epirubicin received was 477±272 mg/m2(range: 200–1200 mg/m2). Of 27 evaluable patients (WHO criteria), 13 had a partial response (48%), 4 showed no change (15%), and 10 had progressive disease (37%). Median time to progression was 27 weeks. Of 27 patients evaluable for toxicity. hemato-logical toxicity at day 21 was mild. Nonhematological toxicities consisted of nausea and vomiting in 82% of patients (WHO grade 3–4 = 19%). stomatitis in 44.5% (WHO grade 3 = 7.5%), and alopecia in 96% (WHO grade 2–3 = 89%). Appearance of cardiac dysfunction without heart failure during the treatment led to discontinuation of this chemotherapy in 3 patients. The results of this study show that the combination of Epirubicin and Ifosfamide is effective in advanced soft tissue sarcoma with an acceptable toxicity. However, we cannot conclude from this trial whether combination Epirubicin and Ifosfamide is superior to Epirubicin alone.

ISSN:0735-7907    

DOI:10.3109/07357909309024831

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909309024832

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909309024833

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909309024834

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909309024835

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor